Inbrija, the first inhaled levodopa is on the market
Inbrija, the first inhalative levodopa, is on the market. The German pharmacist newspaper writes: “Tremor, rigor, bradykinesia – if the levodopa effect wears off, the typical symptoms reappear in Parkinson's patients. Inbrija is the first inhaled levodopa to quickly improve these off-phenomena - it has been on the EU market since May. Inbrija® has been approved for some time: In September 2019, the European Commission approved the inhaled levodopa preparation, which Parkinson patients:innen Cut off off symptoms after the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended Inbrija® for approval in July 2019. It is now coming onto the German market in May – it is the first inhaled levodopa (L-Dopa) ever.